Leonard Zehr, Author at BioTuesdays

Developments

Maxim survey finds two-thirds of respondents planning to attend JMP

A survey of 150 people to a recent Maxim Group survey about the upcoming J.P. Morgan Healthcare Conference found that 69% of respondents are planning to attend the conference in person, while 52% would choose in person...

September 26, 2022

Developments

iBio acquires RubrYc Therapeutics’ AI drug discovery platform and pipeline

iBio (NYSEA:IBIO) closed the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, marking an important step in iBio’s mission to bring more, and better, immunotherapies to the...

September 21, 2022

Feature

Blue Water Vaccines designing vaccines against infectious diseases

Blue Water Vaccines (NASDAQ:BWV) is building an early-stage pipeline of six transformational vaccine candidates targeting important infectious diseases, including inner ear infections, influenza, norovirus, rotavirus...

September 20, 2022

Developments

Zucara secures Phase 2 funding for hypoglycemia trial

Closely-held Zucara Therapeutics’ positive proof-of-concept data has enabled the company to secure continued funding for a Phase 2 clinical study of ZT-01 to prevent hypoglycemia in people with Type 1 diabetes, which is...

September 19, 2022

Developments

Profound Medical realigns commercial organization to support continued growth

Profound Medical (NASDAQ:PROF; TSX:PRN) has changed its management team and structure to further position the company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed...

September 15, 2022

Developments

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Sigyn Therapeutics (OTCQB:SIGY) plans to pursue first-in-human feasibility studies of its Sigyn Therapy in end-stage renal disease (ESRD) patients suffering from excess inflammation and/or endotoxemia. Sigyn Therapy is...

September 14, 2022

Developments

Fresh Tracks starts Phase 1 MAD study of DYRK1A inhibitor

Fresh Tracks Therapeutics (NASDAQ:FRTX), formerly Brickell Biotech, initiated the multiple ascending dose (MAD) portion of the ongoing Phase 1 clinical trial in Canada, evaluating FRTX-02, its lead drug candidate, in...

September 13, 2022

Feature

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

SAB Biotherapeutics (NASDAQ:SABS) is developing its novel DiversitAb platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies, without the need for human donors.

September 13, 2022

Developments

POINT Biopharma presents early Phase 3 prostate cancer data

POINT Biopharma Global (NASDAQ:PNT) published a poster at ESMO Congress 2022 containing updated efficacy and safety data from the 27-patient safety and dosimetry lead-in cohort for the company’s Phase 3 SPLASH...

September 12, 2022

Developments

Vistagen continuing second Phase 3 trial in social anxiety disorder

Vistagen Therapeutics (NASDAQ:VTGN) announced completion of an interim analysis of PALISADE-2, its second Phase 3 clinical trial assessing drug candidate, PH94B, as an acute treatment of anxiety in adults with social...

September 8, 2022

Author - Leonard Zehr

Maxim survey finds two-thirds of respondents planning to attend JMP

iBio acquires RubrYc Therapeutics’ AI drug discovery platform and pipeline

Blue Water Vaccines designing vaccines against infectious diseases

Zucara secures Phase 2 funding for hypoglycemia trial

Profound Medical realigns commercial organization to support continued growth

Sigyn Therapeutics to pursue first-In-human studies in end-stage renal disease

Fresh Tracks starts Phase 1 MAD study of DYRK1A inhibitor

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

POINT Biopharma presents early Phase 3 prostate cancer data

Vistagen continuing second Phase 3 trial in social anxiety disorder

General

More